News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Exelixis, Inc. Says Quickly Filled Spots in Cancer Trial
January 11, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
SAN FRANCISCO, Jan 10 (Reuters) - Exelixis Inc (EXEL.O: Quote, Profile, Research) said it quickly attracted patients with non-small cell lung cancer for a trial of its experimental cancer drug XL647, Chief Executive George Scangos said on Thursday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Exelixis, Inc.
MORE ON THIS TOPIC
Cardiovascular disease
Insmed ‘Blows Away Expectations’ With Positive Data for Inhaled Hypertension Therapy
June 11, 2025
·
2 min read
·
Tristan Manalac
Infectious disease
Gilead’s HIV Combo on Hold, With No Impact on FDA’s Pending Lenacapavir Decision
June 10, 2025
·
3 min read
·
Annalee Armstrong
Neurodegenerative disease
Avidity’s siRNA Muscular Dystrophy Drug Improves Mobility, Boosts Muscle Strength
June 9, 2025
·
2 min read
·
Dan Samorodnitsky
Cardiovascular disease
Merck Moves Forward in Bid To Bring First Oral PCSK9 Inhibitor to Market
June 9, 2025
·
2 min read
·
Tristan Manalac
